Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models.
LI Liu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Hong Shi
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Maureen R Bleam
Employment or Leadership Position - GlaxoSmithKline
Vivian Zhang
Stock Ownership - GlaxoSmithKline
Jun Zou
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Junping Jing
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Kurtis E. Bachman
Stock Ownership - GlaxoSmithKline
Monica Motwani
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Keith W. Orford
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Axel Hoos
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline